Loss of function mutations in the tumour suppressor PTEN, or homozygous deletion of PTEN are observed in 5–10% of ER+ breast cancers and genetic activation of AKT-1 occurs in 5–7% of ER+ breast cancers3–5. Here, ESR1 is linked to breast carcinoma.